Ophthalon may be available in the countries listed below.
Chloramphenicol is reported as an ingredient of Ophthalon in the following countries:
Colistin sulphomethate sodium (a derivative of Colistin) is reported as an ingredient of Ophthalon in the following countries:
International Drug Name Search
Clindamicina Fabra may be available in the countries listed below.
Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Clindamicina Fabra in the following countries:
International Drug Name Search
Oxitocinã may be available in the countries listed below.
Oxytocin is reported as an ingredient of Oxitocinã in the following countries:
International Drug Name Search
Robitet may be available in the countries listed below.
Tetracycline hydrochloride (a derivative of Tetracycline) is reported as an ingredient of Robitet in the following countries:
International Drug Name Search
Glipizide is reported as an ingredient of Glipizide with Metformin Hydrochloride in the following countries:
Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Glipizide with Metformin Hydrochloride in the following countries:
International Drug Name Search
This product is a sterile, nonpyrogenic solution containing isotonic concentrations of electrolytes in water for injection. The solution is isotonic. It is administered by intravenous infusion for parenteral replacement of extracellular losses of fluid and electrolytes.
Each 100 mL of Ringer's Injection, USP contains sodium chloride 860 mg, potassium chloride 30 mg and calcium chloride, dihydrate 33 mg. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. A liter provides 147 mEq sodium (Na+), 4 mEq potassium (K+), 4 mEq calcium (Ca++) and 155 mEq chloride (Cl-). The electrolyte content is isotonic (309 mOsmol/liter, calc.) in relation to the extracellular fluid (approx. 280 mOsmol/liter). The pH of the solution is 5.4 (5.0 – 7.5).
The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and is intended only for use as a single-dose injection. When smaller doses are required the unused portion should be discarded.
The solution is a parenteral fluid and electrolyte replenisher.
Calcium Chloride, USP is chemically designated calcium chloride, dihydrate (CaCl2 • 2 H2O), white fragments or granules freely soluble in water.
Potassium Chloride, USP is chemically designated KCl, a white granular powder freely soluble in water.
Sodium Chloride, USP is chemically designated NaCI, a white crystalline powder freely soluble in water.
Water for Injection, USP is chemically designated H2O.
The flexible plastic container is fabricated from a clear multilayer polyolefin plastic film.
When administered intravenously, this solution provides sources of water and electrolytes. Its electrolyte content resembles that of the principal ionic constituents of normal plasma and the solution therefore is suitable for parenteral replacement of extracellular losses of fluid and electrolytes.
Calcium chloride in water dissociates to provide calcium (Ca++) and chloride (Cl-) ions. They are normal constituents of the body fluids and are dependent on various physiologic mechanisms for maintenance of balance between intake and output. Approximately 80% of body calcium is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.
Potassium chloride in water dissociates to provide potassium (K+) and chloride (Cl-) ions. Potassium is found in low concentration in plasma and extracellular fluids (3.5 to 5.0 mEq/liter in a healthy adult). It is the chief cation of body cells (160 mEq/liter of intracellular water). Potassium plays an important role in electrolyte balance. Normally about 80 to 90% of the potassium intake is excreted in the urine; the remainder in the stools and to a small extent, in the perspiration. The kidney does not conserve potassium well so that during fasting or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion.
Sodium chloride in water dissociates to provide sodium (Na+) and chloride (Cl-) ions. Sodium (Na+) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl-) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na+) and chloride (Cl-) are largely under the control of the kidney which maintains a balance between intake and output.
Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).
Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.
This solution is indicated for parenteral replacement of extracellular losses of fluid and electrolytes, as required by the clinical condition of the patient.
Solutions containing calcium ions should not be administered simultaneously through the same administration set as blood because of the likelihood of coagulation.
Solutions which contain potassium should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.
Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.
In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention.
Solutions containing lactate ions should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care where there is an increased level or an impaired utilization of lactate ions, as in severe hepatic insufficiency.
The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions.
The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.
Potassium containing solutions should be used with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease.
Solutions containing lactate ions should be used with caution as excess administration may result in metabolic alkalosis.
Do not administer unless solution is clear and container is undamaged. Discard unused portion.
Pregnancy Category C.
Animal reproduction studies have not been conducted with Ringer's Injection, USP, It is also not known whether this injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This injection should be given to a pregnant woman only if clearly needed.
The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS.
The dose is dependent upon the age, weight and clinical condition of the patient.
Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
The presence of calcium limits their compatibility with certain drugs that form precipitates of calcium salts, and also prohibits their simultaneous infusion through the same administration set as blood because of the likelihood of coagulation.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.
Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired. If supplemental medication is desired, follow directions below before preparing for administration.
To Add Medication
(Use aseptic technique)
Remove blue cap from BLU-MED™ sterile medication additive port at bottom of container.
With a needle of appropriate length, puncture resealable additive port and inject. Withdraw needle after injecting medication.
Mix container contents thoroughly.
The additive port may be protected by an appropriate cover.
Preparation for Administration
(Use aseptic technique)
NOTE: See appropriate I.V. administration set Instructions for Use.
Close flow control clamp of administration set.
Remove cap from sterile administration set port at bottom of container.
Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.
Suspend container.
Squeeze and release drip chamber to establish proper fluid level in chamber.
Open clamp. Eliminate air from remainder of set.
Attach set to patient access device.
Begin infusion.
WARNING: Do not use flexible container in series connections.
This solution is supplied in single-dose flexible plastic containers as follows:
NDC No. | Product Name | Container Size (mL) |
0409-7982-30 | Ringer’s Inj., USP | 500 |
0409-7982-48 | Ringer’s Inj., USP | 1000 |
Protect from freezing. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]
Created: June, 2009 | EN-2172 | |
Printed in USA |
Hospira, Inc., Lake Forest, IL 60045 USA
| Ringers sodium chloride, potassium chloride, and calcium chloride injection, solution | ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA018251 | 10/26/2010 | |
| Labeler - Hospira, Inc. (141588017) |
Triamteren comp.-CT may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Triamteren comp.-CT in the following countries:
Triamterene is reported as an ingredient of Triamteren comp.-CT in the following countries:
International Drug Name Search
Gastal may be available in the countries listed below.
Aluminium Hydroxide is reported as an ingredient of Gastal in the following countries:
Magnesium Carbonate is reported as an ingredient of Gastal in the following countries:
Magnesium Hydroxide is reported as an ingredient of Gastal in the following countries:
International Drug Name Search
Procelac may be available in the countries listed below.
Omeprazole is reported as an ingredient of Procelac in the following countries:
International Drug Name Search
In the US, Exjade (deferasirox systemic) is a member of the drug class chelating agents and is used to treat Hemosiderosis.
US matches:
UK matches:
Deferasirox is reported as an ingredient of Exjade in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
In the US, Fosrenol (lanthanum carbonate systemic) is a member of the drug class minerals and electrolytes and is used to treat Hyperphosphatemia of Renal Failure.
US matches:
UK matches:
Lanthanum Carbonate is reported as an ingredient of Fosrenol in the following countries:
Lanthanum Carbonate hydrate (a derivative of Lanthanum Carbonate) is reported as an ingredient of Fosrenol in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
In the US, FUDR (floxuridine systemic) is a member of the drug class antimetabolites and is used to treat Liver Metastasis in Adenocarcinoma.
US matches:
Floxuridine is reported as an ingredient of FUDR in the following countries:
International Drug Name Search
Oro Rhinathiol may be available in the countries listed below.
Dequalinium Chloride is reported as an ingredient of Oro Rhinathiol in the following countries:
Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Oro Rhinathiol in the following countries:
International Drug Name Search
Bufigen may be available in the countries listed below.
Nalbuphine hydrochloride (a derivative of Nalbuphine) is reported as an ingredient of Bufigen in the following countries:
International Drug Name Search
Parapres may be available in the countries listed below.
Candesartan cilexetil (a derivative of Candesartan) is reported as an ingredient of Parapres in the following countries:
International Drug Name Search
Prop.INN
L01AX02
0000054-91-1
C10-H16-Br2-N2-O2
356
Antineoplastic agent, alkylating agent
Piperazine, 1,4-bis(3-bromo-1-oxopropyl)-
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Prop.INN | Proposed International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Syprine is a brand name of trientine, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Syprine available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Syprine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Syprine.
In the US, Urimax (hyoscyamine/methenamine/methylene blue/phenyl salicylate systemic) is a member of the drug class urinary antispasmodics and is used to treat Urinary Tract Infection.
US matches:
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Urimax in the following countries:
International Drug Name Search
Supositorios Glicerina may be available in the countries listed below.
Glycerol is reported as an ingredient of Supositorios Glicerina in the following countries:
International Drug Name Search
Quinomax may be available in the countries listed below.
Moxifloxacin is reported as an ingredient of Quinomax in the following countries:
Moxifloxacin hydrochloride (a derivative of Moxifloxacin) is reported as an ingredient of Quinomax in the following countries:
Ofloxacin is reported as an ingredient of Quinomax in the following countries:
International Drug Name Search
In the US, Lansoprazole (lansoprazole systemic) is a member of the drug class proton pump inhibitors and is used to treat Aspiration Pneumonia, Barrett's Esophagus, Duodenal Ulcer, Duodenal Ulcer Prophylaxis, Erosive Esophagitis, GERD, Helicobacter Pylori Infection, Multiple Endocrine Adenomas, NSAID-Induced Gastric Ulcer, NSAID-Induced Ulcer Prophylaxis, Stomach Ulcer, Systemic Mastocytosis and Zollinger-Ellison Syndrome.
US matches:
UK matches:
Rec.INN
A02BC03
0103577-45-3
C16-H14-F3-N3-O2-S
369
Gastric acid secretion inhibitor
Treatment of peptic ulcer and gastro-oesophageal reflux disease (GORD)
Proton pump inhibitor, PPI
2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| SPC | Summary of Product Characteristics (UK) |
| USAN | United States Adopted Name |
In the US, Strepsils Chesty Cough is a member of the drug class expectorants and is used to treat Bronchitis and Cough.
Guaifenesin is reported as an ingredient of Strepsils Chesty Cough in the following countries:
International Drug Name Search
Flui-DNCG may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Flui-DNCG in the following countries:
International Drug Name Search
Falcifor may be available in the countries listed below.
Folic Acid is reported as an ingredient of Falcifor in the following countries:
International Drug Name Search
Helmicid may be available in the countries listed below.
Piperazine is reported as an ingredient of Helmicid in the following countries:
Piperazine hexahydrate (a derivative of Piperazine) is reported as an ingredient of Helmicid in the following countries:
International Drug Name Search
Kalium chloratum Sintetica may be available in the countries listed below.
Potassium Chloride is reported as an ingredient of Kalium chloratum Sintetica in the following countries:
International Drug Name Search
Atrimon may be available in the countries listed below.
Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Atrimon in the following countries:
International Drug Name Search
Tenoren may be available in the countries listed below.
Atenolol is reported as an ingredient of Tenoren in the following countries:
International Drug Name Search
Nadiflo may be available in the countries listed below.
Nadifloxacin is reported as an ingredient of Nadiflo in the following countries:
International Drug Name Search
Hormodose may be available in the countries listed below.
Estradiol is reported as an ingredient of Hormodose in the following countries:
International Drug Name Search
Lotemax is a brand name of loteprednol ophthalmic, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Lotemax available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lotemax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
In some countries, this medicine may only be approved for veterinary use.
Rec.INN
0003704-09-4
C20-H30-O2
302
Anabolic
Androgen
Estr-4-en-3-one, 17-hydroxy-7,17-dimethyl-, (7α,17ß)-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
In some countries, this medicine may only be approved for veterinary use.
BP
0007429-90-5
Al
26
Wound healing agent
Dermatological agent: Skin protectant
International Drug Name Search
Glossary
| BP | British Pharmacopoeia |
| IS | Inofficial Synonym |
| PH | Pharmacopoeia Name |
Alprazolam AL may be available in the countries listed below.
Alprazolam is reported as an ingredient of Alprazolam AL in the following countries:
International Drug Name Search
Relieving symptoms of sinus congestion, runny nose, sneezing, and cough due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.
BroveX PB C is a decongestant, antihistamine, and cough suppressant combination. The decongestant works by constricting blood vessels and reducing swelling in the nasal passages. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The cough suppressant works in the brain to help decrease the cough reflex to reduce a dry cough.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with BroveX PB C. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with BroveX PB C. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if BroveX PB C may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use BroveX PB C as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use BroveX PB C.
Some people who use BroveX PB C for a long time may develop a need to continue taking it. People who take high doses are also at risk. This is known as DEPENDENCE or addiction.
If you stop taking BroveX PB C suddenly, you may have WITHDRAWAL symptoms. These may include anxiety, irregular heartbeat, irritability, restlessness, trouble sleeping, and unusual sweating.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; dry mouth, nose, or throat; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; difficulty urinating or inability to urinate; fast, slow, or irregular heartbeat; hallucinations; loss of coordination; mental or mood changes (eg, irritability); ringing in the ears; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; shallow breathing; tremor; trouble sleeping; uncontrolled muscle movements; unusual bruising or bleeding; unusual weakness or tiredness; vision changes or blurred vision.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch .
See also: BroveX PB C side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; cold and clammy skin; coma; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; shallow breathing; unusually fast, slow, or irregular heartbeat; vomiting.
Store BroveX PB C at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep BroveX PB C out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about BroveX PB C. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.